-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA grants priority review to Insmed ARIKAYCE MAC lung disease sNDA, PDUFA set for Jan. 28, 2027

PUBT·09/21/2026 11:01:02
Listen to the news
FDA grants priority review to Insmed ARIKAYCE MAC lung disease sNDA, PDUFA set for Jan. 28, 2027
  • FDA accepted Insmed’s sNDA for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review.
  • PDUFA target action date set for Jan. 28, 2027.
  • Filing seeks full approval, supported by Phase 3b ENCORE results showing improved respiratory symptoms, higher culture conversion versus multidrug therapy alone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210700PR_NEWS_USPR_____NY52070) on September 21, 2026, and is solely responsible for the information contained therein.